TCGA-D8-A1XT-01A-11R-A14M-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 17
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.650
- INTERFERON_GAMMA_RESPONSE+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- INFLAMMATORY_RESPONSE+0.380
- ANGIOGENESIS+0.370
- MITOTIC_SPINDLE+0.350
- MTORC1_SIGNALING+0.340
- PROTEIN_SECRETION+0.280
- TGF_BETA_SIGNALING+0.280
- COMPLEMENT+0.260
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.490
- ESTROGEN_RESPONSE_LATE-0.480
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.280
- KRAS_SIGNALING_DN-0.250
- APICAL_SURFACE-0.220
- PANCREAS_BETA_CELLS-0.180
- MYC_TARGETS_V1-0.170
- PEROXISOME-0.160
- XENOBIOTIC_METABOLISM-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0BW-01A-11R-A115-07 | — | D | 0.823 |
| 2 | TCGA-D8-A27M-01A-11R-A16F-07 | — | D | 0.817 |
| 3 | TCGA-D8-A1JL-01A-11R-A13Q-07 | — | D | 0.807 |
| 4 | 198b23eb-5efa-4c7e-84f6-96976474de0b | — | — | 0.800 |
| 5 | SRR35579823 | — | D | 0.799 |
| 6 | TCGA-44-2668-01A-01R-A278-07 | — | cohortA1 | 0.797 |
| 7 | TCGA-86-8074-01A-11R-2241-07 | — | cohortA1 | 0.795 |
| 8 | TCGA-55-6978-01A-11R-1949-07 | — | cohortA1 | 0.794 |
| 9 | SRR4296088 | — | cohortMD2 | 0.793 |
| 10 | TCGA-BH-A1F0-01A-11R-A137-07 | — | D | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.650 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |